$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

$plrx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000174647322000010 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$1.999M	$7.572M	$4.470M
YoY Change	-55.28%	-81.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.846M	$27.56M	$5.630M
YoY Change	39.36%	59.57%
% of Gross Profit
Research & Development	$18.75M	$77.55M	$17.85M
YoY Change	5.05%	17.16%
% of Gross Profit
Depreciation & Amortization	$418.0K	$1.500M	$350.0K
YoY Change	19.43%	15.38%	-38.6%
% of Gross Profit
Operating Expenses	$26.60M	$105.1M	$23.48M
YoY Change	13.28%	25.93%
Operating Profit		-$97.54M
YoY Change		134.21%
Interest Expense	$68.00K	$0.00	$90.00K
YoY Change	-24.44%	-100.0%
% of Operating Profit
Other Income/Expense, Net			-$100.0K
YoY Change
Pretax Income	-$24.53M	-$97.30M	-$19.03M
YoY Change	28.91%	-334.46%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$24.53M	-$97.26M	-$19.03M
YoY Change	28.91%	134.18%
Net Earnings / Revenue	-1227.16%	-1284.51%	-425.73%
Basic Earnings Per Share		-$2.71
Diluted Earnings Per Share	-$681.0K	-$2.71	-$534.6K
COMMON SHARES
Basic Shares Outstanding	36.04M shares	35.85M shares
Diluted Shares Outstanding		35.85M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$200.6M	$200.6M	$276.9M
YoY Change	-27.56%	-27.56%	169.36%
Cash & Equivalents	$51.67M	$51.67M	$50.88M
Short-Term Investments	$148.9M	$148.9M	$226.0M
Other Short-Term Assets	$6.764M	$6.764M	$4.500M
YoY Change	50.31%	50.31%	164.71%
Inventory
Prepaid Expenses
Receivables	$1.998M	$1.998M	$9.279M
Other Receivables	$83.00K	$83.00K	$100.0K
Total Short-Term Assets	$209.4M	$209.4M	$290.8M
YoY Change	-27.97%	-27.98%	159.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.606M	$10.94M	$4.321M
YoY Change	6.6%	154.33%	5.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$838.0K	$838.0K	$451.0K
YoY Change	85.81%	67.6%	-85.38%
Total Long-Term Assets	$11.77M	$11.77M	$4.772M
YoY Change	146.73%	150.51%	-33.39%
TOTAL ASSETS
Total Short-Term Assets	$209.4M	$209.4M	$290.8M
Total Long-Term Assets	$11.77M	$11.77M	$4.772M
Total Assets	$221.2M	$221.2M	$295.5M
YoY Change	-25.15%	-25.14%	148.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.971M	$2.971M	$2.023M
YoY Change	46.86%	48.55%	61.84%
Accrued Expenses	$11.99M	$11.99M	$9.576M
YoY Change	25.22%	24.91%	38.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.869M	$1.869M
YoY Change
Total Short-Term Liabilities	$16.83M	$16.83M	$11.60M
YoY Change	45.11%	45.09%	41.94%
LONG-TERM LIABILITIES
Long-Term Debt	$5.325M	$5.325M	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$866.0K
YoY Change	-100.0%	-100.0%	-5.04%
Total Long-Term Liabilities	$0.00	$5.325M	$866.0K
YoY Change	-100.0%	491.67%	-5.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.83M	$16.83M	$11.60M
Total Long-Term Liabilities	$0.00	$5.325M	$866.0K
Total Liabilities	$22.16M	$22.16M	$12.47M
YoY Change	77.75%	77.25%	37.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$215.1M		-$117.8M
YoY Change	82.55%		54.44%
Common Stock	$414.4M		$400.9M
YoY Change	3.35%		40092000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$199.1M	$199.1M	$283.1M
YoY Change
Total Liabilities & Shareholders Equity	$221.2M	$221.2M	$295.5M
YoY Change	-25.15%	-25.14%	148.21%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$24.53M	-$97.26M	-$19.03M
YoY Change	28.91%	134.18%
Depreciation, Depletion And Amortization	$418.0K	$1.500M	$350.0K
YoY Change	19.43%	15.38%	-38.6%
Cash From Operating Activities	-$19.86M	-$75.44M	-$16.48M
YoY Change	20.54%	102.42%	-175.35%
INVESTING ACTIVITIES
Capital Expenditures	-$592.0K	$1.953M	-$580.0K
YoY Change	2.07%	27.48%	152.17%
Acquisitions
YoY Change
Other Investing Activities	$26.38M	$75.65M	$12.50M
YoY Change	111.0%	-136.14%	160.42%
Cash From Investing Activities	$25.78M	$73.70M	$11.90M
YoY Change	116.66%	-134.95%	160.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	516.0K	$2.527M	230.0K
YoY Change	124.35%	-98.81%	-99.5%
NET CHANGE
Cash From Operating Activities	-19.86M	-$75.44M	-16.48M
Cash From Investing Activities	25.78M	$73.70M	11.90M
Cash From Financing Activities	516.0K	$2.527M	230.0K
Net Change In Cash	6.434M	$783.0K	-4.350M
YoY Change	-247.91%	-102.24%	-105.97%
FREE CASH FLOW
Cash From Operating Activities	-$19.86M	-$75.44M	-$16.48M
Capital Expenditures	-$592.0K	$1.953M	-$580.0K
Free Cash Flow	-$19.27M	-$77.40M	-$15.90M
YoY Change	21.21%	99.46%	-171.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001746473
CY2020Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.13986014
CY2021	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	http://fasb.org/us-gaap/2021-01-31#RetirementPlanNameOtherMember
CY2020	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	http://fasb.org/us-gaap/2021-01-31#RetirementPlanNameOtherMember
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39303
CY2021	dei	Entity Registrant Name EntityRegistrantName	PLIANT THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4272481
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Littlefield Avenue
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	481-6770
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021	dei	Trading Symbol TradingSymbol	PLRX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	751814002	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36113521	shares
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Location AuditorLocation	San Francisco, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51665000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50882000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	148931000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	226012000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1998000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9279000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6764000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4498000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	209441000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	290754000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4606000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4321000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6330000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	838000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	451000	USD
CY2021Q4	us-gaap	Assets Assets	221215000	USD
CY2020Q4	us-gaap	Assets Assets	295526000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2971000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2023000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11991000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9576000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1869000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16831000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	12465000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11599000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5325000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	866000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	22156000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36083301	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36083301	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35552795	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35552795	shares
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-215091000	USD
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	3000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	3000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	414348000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	400918000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-117828000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-201000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	199059000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	283061000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	221215000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	295526000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7572000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41817000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57052000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77549000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66193000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	105107000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47353000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27558000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17269000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10930000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	83462000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	58283000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-97535000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-41645000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-1231000	USD
CY2021	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	272000	USD
CY2020	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	112000	USD
CY2019	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	600000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-97263000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41533000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-631000	USD
CY2021	plrx	Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock	0	USD
CY2020	plrx	Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock	0	USD
CY2019	plrx	Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock	6225000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97263000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41533000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6856000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.71
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.95
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.22
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.71
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.95
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.22
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35846421	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21344236	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1623358	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35846421	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21344236	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1623358	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-97263000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41533000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-631000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-169000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-31000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97432000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41564000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-632000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	283061000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	9000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2984000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10437000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-97263000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	199059000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-76295000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	238294000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	442000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3895000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41533000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	283061000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-71469000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	174000	USD
CY2019	plrx	Accretion To Redemption Value And Cumulative Dividend On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock	6225000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1829000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-631000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-76295000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-97263000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-41533000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-631000	USD
CY2021	us-gaap	Depreciation Depreciation	1535000	USD
CY2020	us-gaap	Depreciation Depreciation	1310000	USD
CY2019	us-gaap	Depreciation Depreciation	1113000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10437000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3895000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1829000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1669000	USD
CY2021	plrx	Other Losses OtherLosses	1262000	USD
CY2020	plrx	Other Losses OtherLosses	266000	USD
CY2019	plrx	Other Losses OtherLosses	0	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-250000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-167000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7281000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2227000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7052000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2266000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2756000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1458000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-70000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	70000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-232000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	891000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	922000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1255000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2695000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2689000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4255000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1754000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-17000	USD
CY2019	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	50000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-75443000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37271000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2750000	USD
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	219887000	USD
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	322605000	USD
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	51713000	USD
CY2021	plrx	Accretion Of Short Term Investments AccretionOfShortTermInvestments	0	USD
CY2020	plrx	Accretion Of Short Term Investments AccretionOfShortTermInvestments	0	USD
CY2019	plrx	Accretion Of Short Term Investments AccretionOfShortTermInvestments	254000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	295539000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	113271000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	35000000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1953000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1532000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	964000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	73699000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-210866000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17931000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	150751000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	52019000	USD
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	47947000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2984000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	442000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	174000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	457000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2582000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2527000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	213212000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34925000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	24858000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45539000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	783000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50882000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85807000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60949000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51665000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50882000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85807000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	188000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	159000	USD
CY2021	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	9000	USD
CY2020	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	11000	USD
CY2019	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	30000	USD
CY2021	plrx	Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock	0	USD
CY2020	plrx	Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock	0	USD
CY2019	plrx	Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock	6225000	USD
CY2021	plrx	Deferred Offering Costs In Accounts Payable And Accrued Liabilities DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities	0	USD
CY2020	plrx	Deferred Offering Costs In Accounts Payable And Accrued Liabilities DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities	0	USD
CY2019	plrx	Deferred Offering Costs In Accounts Payable And Accrued Liabilities DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities	230000	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-169000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-31000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets and liabilities, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the years ended December 31, 2021, 2020 and 2019, Novartis accounted for 100% of the Company’s revenue and accounts receivable.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results of operations involve several other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></div>
CY2019	plrx	Percentage Of Revenue Contributed By Related Party PercentageOfRevenueContributedByRelatedParty	1
CY2021	plrx	Percentage Of Revenue Contributed By Related Party PercentageOfRevenueContributedByRelatedParty	1
CY2020	plrx	Percentage Of Revenue Contributed By Related Party PercentageOfRevenueContributedByRelatedParty	1
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	plrx	Debt Instrument Remaining Maturity Period At Date Of Purchase DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase	P3M
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	183958000	USD
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	1000	USD
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	202000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	183757000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	263729000	USD
CY2020	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	15000	USD
CY2020	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	47000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	263697000	USD
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9625000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7809000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5019000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3488000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4606000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4321000	USD
CY2021	us-gaap	Depreciation Depreciation	1500000	USD
CY2020	us-gaap	Depreciation Depreciation	1300000	USD
CY2019	us-gaap	Depreciation Depreciation	1100000	USD
CY2021Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2819000	USD
CY2020Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	1898000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2585000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1459000	USD
CY2021Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	819000	USD
CY2020Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	665000	USD
CY2021Q4	us-gaap	Prepaid Interest PrepaidInterest	385000	USD
CY2020Q4	us-gaap	Prepaid Interest PrepaidInterest	386000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	156000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	90000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6764000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4498000	USD
CY2021Q4	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	5868000	USD
CY2020Q4	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	3274000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5216000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4542000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	907000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1675000	USD
CY2021Q4	plrx	Deferred Rent And Leasehold Incentive Obligation Current DeferredRentAndLeaseholdIncentiveObligationCurrent	0	USD
CY2020Q4	plrx	Deferred Rent And Leasehold Incentive Obligation Current DeferredRentAndLeaseholdIncentiveObligationCurrent	85000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11991000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9576000	USD
CY2021Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	0	USD
CY2020Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	581000	USD
CY2021Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	0	USD
CY2020Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	283000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	866000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	plrx	Number Of Votes Per Share Of Common Stock NumberOfVotesPerShareOfCommonStock	1	vote
CY2021	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8467491	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7338314	shares
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10437000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3895000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1829000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-97300000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	41500000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	600000	USD
CY2021Q4	plrx	Valuation Allowance As Percentage On Deferred Tax Assets ValuationAllowanceAsPercentageOnDeferredTaxAssets	1
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.074
CY2021	plrx	Effective Income Tax Rate Reconciliation General Business Tax Credits Federal EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal	0.053
CY2020	plrx	Effective Income Tax Rate Reconciliation General Business Tax Credits Federal EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal	0.053
CY2019	plrx	Effective Income Tax Rate Reconciliation General Business Tax Credits Federal EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal	2.959
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.500
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.024
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.332
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.326
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2.677
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51554000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27047000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	13989000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7617000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	292000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	291000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	775000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	474000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	266000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1202000	USD
CY2021Q4	plrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2000000	USD
CY2020Q4	plrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1816000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	428000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70426000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36123000	USD
CY2021Q4	plrx	Deferred Tax Liabilities Fixed Asset Basis DeferredTaxLiabilitiesFixedAssetBasis	61000	USD
CY2020Q4	plrx	Deferred Tax Liabilities Fixed Asset Basis DeferredTaxLiabilitiesFixedAssetBasis	124000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	921000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	558000	USD
CY2021Q4	plrx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1760000	USD
CY2020Q4	plrx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2742000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	682000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67684000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35441000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35441000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21929000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	32243000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13512000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67684000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35441000	USD
CY2021	plrx	Income Tax Examination Number Of Examinations Pending IncomeTaxExaminationNumberOfExaminationsPending	0	taxExamination
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2007000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1355000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	855000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1081000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	513000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	570000	USD
CY2021	plrx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	417000	USD
CY2020	plrx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	139000	USD
CY2019	plrx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-70000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3505000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2007000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1355000	USD
CY2021	plrx	Contractual Arrangements Cancellation Period ContractualArrangementsCancellationPeriod	P30D
CY2018Q1	plrx	Period Of Base Rent Abatement PeriodOfBaseRentAbatement	P2M
CY2018Q1	plrx	Base Rent Abated Amount BaseRentAbatedAmount	200000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2300000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	900000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2400000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2360000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2295000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2365000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7194000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8222000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1028000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0790
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2500000	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2500000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3642021	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3124572	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20086140	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-97263000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-41533000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-631000	USD
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	6225000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97263000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41533000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6856000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35846421	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21344236	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1623358	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35846421	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21344236	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1623358	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.71
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.95
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.22
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.71
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.95
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.22

Files In Submission

Name	View Source	Status
0001746473-22-000010-index-headers.html	Edgar Link	pending
0001746473-22-000010-index.html	Edgar Link	pending
0001746473-22-000010.txt	Edgar Link	pending
0001746473-22-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
non-employeedirectorcompen.htm	Edgar Link	pending
plrx-20211231.htm	Edgar Link	pending
plrx-20211231.xsd	Edgar Link	pending
plrx-20211231_cal.xml	Edgar Link	unprocessable
plrx-20211231_def.xml	Edgar Link	unprocessable
plrx-20211231_g1.jpg	Edgar Link	pending
plrx-20211231_g10.jpg	Edgar Link	pending
plrx-20211231_g11.jpg	Edgar Link	pending
plrx-20211231_g12.jpg	Edgar Link	pending
plrx-20211231_g13.jpg	Edgar Link	pending
plrx-20211231_g14.jpg	Edgar Link	pending
plrx-20211231_g15.jpg	Edgar Link	pending
plrx-20211231_g16.jpg	Edgar Link	pending
plrx-20211231_g17.jpg	Edgar Link	pending
plrx-20211231_g18.jpg	Edgar Link	pending
plrx-20211231_g19.jpg	Edgar Link	pending
plrx-20211231_g2.jpg	Edgar Link	pending
plrx-20211231_g20.gif	Edgar Link	pending
plrx-20211231_g21.jpg	Edgar Link	pending
plrx-20211231_g22.jpg	Edgar Link	pending
plrx-20211231_g23.jpg	Edgar Link	pending
plrx-20211231_g24.gif	Edgar Link	pending
plrx-20211231_g25.gif	Edgar Link	pending
plrx-20211231_g26.jpg	Edgar Link	pending
plrx-20211231_g27.jpg	Edgar Link	pending
plrx-20211231_g3.jpg	Edgar Link	pending
plrx-20211231_g4.jpg	Edgar Link	pending
plrx-20211231_g5.jpg	Edgar Link	pending
plrx-20211231_g6.jpg	Edgar Link	pending
plrx-20211231_g7.jpg	Edgar Link	pending
plrx-20211231_g8.jpg	Edgar Link	pending
plrx-20211231_g9.jpg	Edgar Link	pending
plrx-20211231_htm.xml	Edgar Link	completed
plrx-20211231_lab.xml	Edgar Link	unprocessable
plrx-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ye2021-ex312.htm	Edgar Link	pending
ye2021-ex321.htm	Edgar Link	pending
ye2021ex311.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

2021 Q4 Form 10-K Financial Statement

#000174647322000010 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX PLIANT THERAPEUTICS, INC. Stock $plrx

2021 Q4 Form 10-K Financial Statement

#000174647322000010 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx